Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis

Jing Shi, Erika Darrah, Gary P. Sims, Tomas Mustelin, Kevon Sampson, Maximilian F. Konig, Clifton Bingham, Antony Rosen, Felipe A Andrade

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: The citrullinating enzyme peptidylarginine deiminase type 4 (PAD4) is the target of a polyclonal group of autoantibodies in patients with rheumatoid arthritis (RA). A subgroup of such antibodies, initially identified by cross-reactivity with peptidylarginine deiminase type 3 (PAD3), is strongly associated with progression of radiographic joint damage and interstitial lung disease and has the unique ability to activate PAD4. The features of these antibodies in terms of their T cell-dependent origin, genetic characteristics and effect of individual antibody specificities on PAD4 function remain to be defined.

METHODS: We used PAD4 tagged with the monomeric fluorescent protein mWasabi to isolate PAD4-specific memory B cells from anti-PAD4 positive patients with RA and applied single cell cloning technologies to obtain monoclonal antibodies.

RESULTS: Among 44 single B cells, we cloned five antibodies with PAD4-activating properties. Sequence analysis, germline reversion experiments and antigen specificity assays suggested that autoantibodies to PAD4 are not polyreactive and arise from PAD4-reactive precursors. Somatic mutations increase the agonistic activity of these antibodies at low calcium concentrations by facilitating their interaction with structural epitopes that modulate calcium-binding site 5 in PAD4.

CONCLUSIONS: PAD4-activating antibodies directly amplify a key process in disease pathogenesis, making them unique among other autoantibodies in RA. Understanding the molecular basis for their functionality may inform the design of future PAD4 inhibitors.

Original languageEnglish (US)
Pages (from-to)141-148
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume77
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Rheumatoid Arthritis
Antibodies
Autoantibodies
protein-arginine deiminase
B-Lymphocytes
Cells
Calcium
Pulmonary diseases
Antibody Specificity
T-cells
Cloning
Interstitial Lung Diseases
Sequence Analysis
Organism Cloning
Epitopes
Assays
Joints
Binding Sites
Monoclonal Antibodies
Technology

Keywords

  • ant-ccp
  • autoantibodies
  • autoimmune diseases
  • autoimmunity
  • rheumatoid Arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis. / Shi, Jing; Darrah, Erika; Sims, Gary P.; Mustelin, Tomas; Sampson, Kevon; Konig, Maximilian F.; Bingham, Clifton; Rosen, Antony; Andrade, Felipe A.

In: Annals of the Rheumatic Diseases, Vol. 77, No. 1, 01.01.2018, p. 141-148.

Research output: Contribution to journalArticle

@article{ed273154b852493881ea69420364d074,
title = "Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis",
abstract = "OBJECTIVES: The citrullinating enzyme peptidylarginine deiminase type 4 (PAD4) is the target of a polyclonal group of autoantibodies in patients with rheumatoid arthritis (RA). A subgroup of such antibodies, initially identified by cross-reactivity with peptidylarginine deiminase type 3 (PAD3), is strongly associated with progression of radiographic joint damage and interstitial lung disease and has the unique ability to activate PAD4. The features of these antibodies in terms of their T cell-dependent origin, genetic characteristics and effect of individual antibody specificities on PAD4 function remain to be defined.METHODS: We used PAD4 tagged with the monomeric fluorescent protein mWasabi to isolate PAD4-specific memory B cells from anti-PAD4 positive patients with RA and applied single cell cloning technologies to obtain monoclonal antibodies.RESULTS: Among 44 single B cells, we cloned five antibodies with PAD4-activating properties. Sequence analysis, germline reversion experiments and antigen specificity assays suggested that autoantibodies to PAD4 are not polyreactive and arise from PAD4-reactive precursors. Somatic mutations increase the agonistic activity of these antibodies at low calcium concentrations by facilitating their interaction with structural epitopes that modulate calcium-binding site 5 in PAD4.CONCLUSIONS: PAD4-activating antibodies directly amplify a key process in disease pathogenesis, making them unique among other autoantibodies in RA. Understanding the molecular basis for their functionality may inform the design of future PAD4 inhibitors.",
keywords = "ant-ccp, autoantibodies, autoimmune diseases, autoimmunity, rheumatoid Arthritis",
author = "Jing Shi and Erika Darrah and Sims, {Gary P.} and Tomas Mustelin and Kevon Sampson and Konig, {Maximilian F.} and Clifton Bingham and Antony Rosen and Andrade, {Felipe A}",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/annrheumdis-2017-211489",
language = "English (US)",
volume = "77",
pages = "141--148",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis

AU - Shi, Jing

AU - Darrah, Erika

AU - Sims, Gary P.

AU - Mustelin, Tomas

AU - Sampson, Kevon

AU - Konig, Maximilian F.

AU - Bingham, Clifton

AU - Rosen, Antony

AU - Andrade, Felipe A

PY - 2018/1/1

Y1 - 2018/1/1

N2 - OBJECTIVES: The citrullinating enzyme peptidylarginine deiminase type 4 (PAD4) is the target of a polyclonal group of autoantibodies in patients with rheumatoid arthritis (RA). A subgroup of such antibodies, initially identified by cross-reactivity with peptidylarginine deiminase type 3 (PAD3), is strongly associated with progression of radiographic joint damage and interstitial lung disease and has the unique ability to activate PAD4. The features of these antibodies in terms of their T cell-dependent origin, genetic characteristics and effect of individual antibody specificities on PAD4 function remain to be defined.METHODS: We used PAD4 tagged with the monomeric fluorescent protein mWasabi to isolate PAD4-specific memory B cells from anti-PAD4 positive patients with RA and applied single cell cloning technologies to obtain monoclonal antibodies.RESULTS: Among 44 single B cells, we cloned five antibodies with PAD4-activating properties. Sequence analysis, germline reversion experiments and antigen specificity assays suggested that autoantibodies to PAD4 are not polyreactive and arise from PAD4-reactive precursors. Somatic mutations increase the agonistic activity of these antibodies at low calcium concentrations by facilitating their interaction with structural epitopes that modulate calcium-binding site 5 in PAD4.CONCLUSIONS: PAD4-activating antibodies directly amplify a key process in disease pathogenesis, making them unique among other autoantibodies in RA. Understanding the molecular basis for their functionality may inform the design of future PAD4 inhibitors.

AB - OBJECTIVES: The citrullinating enzyme peptidylarginine deiminase type 4 (PAD4) is the target of a polyclonal group of autoantibodies in patients with rheumatoid arthritis (RA). A subgroup of such antibodies, initially identified by cross-reactivity with peptidylarginine deiminase type 3 (PAD3), is strongly associated with progression of radiographic joint damage and interstitial lung disease and has the unique ability to activate PAD4. The features of these antibodies in terms of their T cell-dependent origin, genetic characteristics and effect of individual antibody specificities on PAD4 function remain to be defined.METHODS: We used PAD4 tagged with the monomeric fluorescent protein mWasabi to isolate PAD4-specific memory B cells from anti-PAD4 positive patients with RA and applied single cell cloning technologies to obtain monoclonal antibodies.RESULTS: Among 44 single B cells, we cloned five antibodies with PAD4-activating properties. Sequence analysis, germline reversion experiments and antigen specificity assays suggested that autoantibodies to PAD4 are not polyreactive and arise from PAD4-reactive precursors. Somatic mutations increase the agonistic activity of these antibodies at low calcium concentrations by facilitating their interaction with structural epitopes that modulate calcium-binding site 5 in PAD4.CONCLUSIONS: PAD4-activating antibodies directly amplify a key process in disease pathogenesis, making them unique among other autoantibodies in RA. Understanding the molecular basis for their functionality may inform the design of future PAD4 inhibitors.

KW - ant-ccp

KW - autoantibodies

KW - autoimmune diseases

KW - autoimmunity

KW - rheumatoid Arthritis

UR - http://www.scopus.com/inward/record.url?scp=85038248681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038248681&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2017-211489

DO - 10.1136/annrheumdis-2017-211489

M3 - Article

C2 - 29070531

AN - SCOPUS:85038248681

VL - 77

SP - 141

EP - 148

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -